B. O'Brien

发表

Post-Treatment Imaging Changes in Primary Brain Tumors

R. Colen, B. O'Brien, B. O’Brien, 2014, Current Oncology Reports.

Wound healing complications in brain tumor patients on Bevacizumab

M. Gilbert, C. Conrad, M. Fields, 2015, Journal of Neuro-Oncology.

Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma

E. Leuthardt, R. Strowd, J. D. de Groot, 2022, Neuro-oncology advances.

Profiles of brain metastases: Prioritization of therapeutic targets

R. Verhaak, P. Brastianos, N. Ibrahim, 2018, International journal of cancer.

Patterns of failure after radiation therapy in primary spinal high-grade gliomas: A single institutional analysis

Jeffery S. Weinberg, Jason M. Johnson, S. McGovern, 2022, Neuro-oncology advances.

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

P. Wen, T. Cloughesy, L. Liau, 2018, Nature Medicine.

Current chemotherapeutic regimens for brain metastases treatment

B. O'Brien, J. Nam, B. O’Brien, 2017, Clinical & Experimental Metastasis.

A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma

Diane D. Liu, W. Yung, M. Gilbert, 2016, Journal of Neuro-Oncology.

The Role of Immune Checkpoint Inhibitors in Leptomeningeal Disease: A Systematic Review

K. Yu, A. Cohen-Gadol, S. Aoun, 2021, AntiCancer Research.

Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages.

G. Fuller, J. Huse, G. Rao, 2019, Neuro-oncology.

Targeted Therapy in Solid Tumors: Brain

W. Yung, J. Groot, B. O'Brien, 2015 .

Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II Trial

G. Fuller, J. Huse, G. Rao, 2020, Clinical Cancer Research.

Targeting the Tumor Microenvironment in Brain Metastasis.

A. Heimberger, S. Ferguson, I. G. Glitza Oliva, 2020, Neurosurgery clinics of North America.

Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results

J. McQuade, J. Wargo, R. Amaria, 2023, Nature Medicine.

Aggressiveness of care at end of life in patients with high‐grade glioma

E. Bruera, J. D. de Groot, S. Naqvi, 2021, Cancer medicine.

NEURO/MEDICAL ONCOLOGY

Scott N. Hwang, Katrina H. Smith, Susan M. Chang, 2013 .

Clinical trial participation of patients with glioblastoma at The University of Texas MD Anderson Cancer Center.

Mark D. Anderson, J. D. de Groot, Ying Yuan, 2019, European journal of cancer.

Associations of meaning of illness with psychosocial, clinical, and immunological characteristics in patients with Leptomeningeal metastasis

M. Gilbert, C. Fagundes, Jimin Wu, 2021, Comprehensive psychoneuroendocrinology.

Is immuno-oncology therapy effective in hypermutator glioblastomas with somatic or germline mutations?

W. Yung, F. Meric-Bernstam, K. Shaw, 2019, Annals of Oncology.

INNV-21. COMPLETE RESPONSE TO ADJUVANT TEPOTINIB IN A PATIENT WITH NEWLY DIAGNOSED DISSEMINATED GLIOBLASTOMA (GBM) HARBORING MET AMPLIFICATION

J. Degroot, Alexander Ou, B. O'Brien, 2021, Neuro-Oncology.

Single-center phase I/Ib study of concurrent intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).

J. Lee, H. Tawbi, E. Burton, 2020 .

Phase 1 lead‐in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma

K. Aldape, M. Gilbert, K. Hess, 2018, Cancer.

Burnout and Career Satisfaction in Neuro-Oncology: A Survey of the Society for Neuro-Oncology and the European Association of Neuro-Oncology Membership.

M. Weller, T. Armstrong, A. Acquaye, 2019, Neuro-oncology.

A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma

T. MacDonald, G. Fuller, Raymond Sawaya, 2022, CNS oncology.

Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD)

H. Tawbi, L. Haydu, M. Tetzlaff, 2019, Journal of Neuro-Oncology.

Phase I/II study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM).

Diane D. Liu, W. Yung, S. Dervin, 2020 .

Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma.

G. Fuller, J. Huse, G. Rao, 2018 .

Seizure burden pre- and postresection of low-grade gliomas as a predictor of tumor progression in low-grade gliomas.

Nicholas B. Levine, Diane D. Liu, L. Kwong, 2018, Neuro-oncology practice.

Association of Emotional Exhaustion With Career Burnout Among Early-Career Medical Oncologists: A Single-Institution Study.

E. Bruera, A. Shah, Lianchun Xiao, 2023, JCO oncology practice.

Current chemotherapeutic regimens for brain metastases treatment

B. O'Brien, J. Nam, 2017, Clinical & Experimental Metastasis.

Predictors of survival in metastatic melanoma patients with leptomeningeal disease (LMD)

H. Tawbi, L. Haydu, M. Tetzlaff, 2019, Journal of Neuro-Oncology.

Primary Brain Tumors

M. Gilbert, B. O'Brien, 2014 .

Prospective validation of a new imaging scorecard to assess leptomeningeal metastasis: a joint EORTC BTG and RANO effort.

P. Wen, M. J. van den Bent, N. Galldiks, 2022, Neuro-oncology.

Abstract PD4-02: Safety and efficacy of a tucatinib-trastuzumab-capecitabine regimen for treatment of leptomeningeal metastasis (LM) in HER2-positive breast cancer: Results from TBCRC049, a phase 2 non-randomized study

Jason M. Johnson, V. Valero, A. Wolff, 2022, Cancer Research.

Analysis of tumor progression among patients with glioma after COVID-19 infection.

Chirag B. Patel, V. Puduvalli, C. Kamiya-Matsuoka, 2023, Journal of Clinical Oncology.